The study consists of two steps: Step 1, the therapeutic study phase, comprising six cycles of treatment with temozolomide, and Step 2, the long-term treatment phase, where subjects with at least disease stabilization at the end of Step 1 may continue temozolomide treatment until unacceptable toxicity or disease progression occur, up to a maximum of 2 years from the start of treatment in Cycle 1.